Urinary exosomal expression of long non-coding RNAs as diagnostic marker in bladder cancer

Yazarlou, Fatemeh; Modarressi, Mohammad Hossein; Mowla, Seyed Javad; Oskooei, Vahid Kholghi; Motevaseli, Elahe; Tooli, Leila Farhady; Nekoohesh, Leila; Eghbali, Mohammad; Ghafouri‐Fard, Soudeh; Afsharpad, Mandana

doi:10.2147/cmar.s186108

Cited by 73 publications

(79 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past decades, integrated medical-biological technologies were utilized to probe effective treatment method on patients with BLCA. 28 For instance, GAS5 tumor-suppressor lncRNA has been discovered the potential to improve the treatment outcome in patients with BLCA. 27 In addition, there is growing evidence that lncRNA might act as prognostic indicators in BLCA development and progression.…”

Section: Discussionmentioning

confidence: 99%

Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma

Zhang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Nowadays, an increasing number of studies illustrated that bladder urothelial cancer (BLCA) may act as the most common subtype of urological malignancies with a high rate of recurrence and metastasis. In this study, we attempted to establish a prognostic model and identify the possible pathway crosstalk. Long noncoding RNAs (lncRNAs) and mRNA expression and corresponding clinical information of patients with BLCA were downloaded from The Cancer Genome Atlas (TCGA). The differentially expressed genes analysis, univariate Cox analysis, the least absolute shrinkage, and selection operator Cox (LASSO Cox) regression model were then applied to identify five crucial lncRNAs (AC092725.1, AC104071.1, AL023584.1, AL132642.1, and AL137804.1). The multivariate cox analysis was utilized to calculate the regression coefficients (βi). The risk‐score model was subsequently constructed as follows: (0.13541AC092725.1) + (0.20968AC104071.1) + (0.1525AL023584.1) − (0.14768AL132642.1) + (0.14387AL137804.1). Nomogram and assessment of overall survival (OS) prediction were verificated by the receiver operating characteristic curve in the testing group. As to 3‐, 5‐year OS prediction, the area under curve (AUC) for the nomogram of training data set was 0.83 and 0.86. Besides, the AUC (0.883 and 0.879) presented excellent predictive power in the testing group. In addition, the calibration plots validated the predictive performance of the nomogram. Weighted correlation network analysis (WGCNA) coupled with functional enrichment analysis contributed to explore the potential pathways, including PI3K‐Akt, HIF‐1, and Jak‐STAT signaling pathways. Construction of the risk‐score model and data analysis were both derived from multiple packages on the basis of the R platform chiefly.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma

Zhang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…Recently, several reports have highlighted the role of long non-coding RNAs (lncRNAs) as urine-based biomarkers for diagnosis of bladder cancer [1,[10][11][12][13][14][15][16][17][18][19][20][21][22]. Long non-coding RNAs are transcripts longer than 200 nucleotides that are not translated into protein [23].…”

Section: Ivyspring International Publishermentioning

confidence: 99%

“…Another study [14] showed that overexpression of several lncRNAs, such as HOTAIR, HOX-AS-2, MALAT1, HYMAI, LINC00477, LOC100506688 and OTX2-AS1, has been found in urine exosomes of high-grade MIBC patients. Several other studies [10,12] also proposed various panels of lncRNAs as liquid biopsy biomarkers to discriminate bladder cancer patients from healthy controls.…”

Section: Ivyspring International Publishermentioning

confidence: 99%

“…Encouraged by these successes, in this study, we attempted to discover and evaluate the prediction power of a panel of lncRNAs biomarkers to discriminate bladder cancer from urocystitis. We chose totally sixteen lncRNAs as our candidate biomarkers, as suggested by previous studies [1,[10][11][12][13][14][15][16][17][18][19][20][21][22]. We conducted a study of 140 NMIBC patients and 140 urocystitis patients.…”

Section: Ivyspring International Publishermentioning

confidence: 99%

“…The NMIBC cancer group consisted of 140 NMIBC patients, while the urocystitis group consisted of 140 patients diagnosed with severe urocystitis with RUA. These candidate lncRNA biomarkers were selected because they have been previously reported to be able to discriminate bladder cancer patients from healthy controls [10,12,14]. We compared the extracellular expression levels of each candidate biomarker in urine between NMIBC group and urocystitis group.…”

Section: Evaluating Expression Profiles Of Candidate Lncrna Biomarkermentioning

confidence: 99%

See 2 more Smart Citations

A Panel of Urinary Long Non-coding RNAs Differentiate Bladder Cancer from Urocystitis

Yu¹,

Wang²,

Han³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Liquid biopsy is becoming a promising method for non-invasive cancer detection. In several proof-of-concept studies, long non-coding RNAs (lncRNAs) were found to be potential biomarkers for bladder cancer detection. The objective of this study was to discover a panel of cell-free, urinary lncRNAs as liquid biopsy biomarkers to non-invasively differentiate bladder cancer from chronic urocystitis. To this end, we collected urine samples from both bladder cancer patients and urocystitis patients. These samples were divided into discovery group and validation group. In the discovery group, the expression levels of 16 cell-free urinary lncRNAs were measured by qPCR to discover candidate biomarkers. The diagnostic performance of the candidate lncRNA biomarkers was then evaluated, which led to a panel of lncRNA biomarkers for bladder cancer detection. The performance of this panel of biomarkers was further evaluated in the validation group to see if these lncRNA biomarkers could discriminate the bladder cancer patients from urocystitis patients. We found that all of the 16 lncRNAs evaluated in this study demonstrated significant difference (p<0.05) of expression between bladder cancer patients and urocystitis patients. Nine lncRNAs provided decent diagnostic performance with area under the receiver operating characteristic (ROC) curve (AUC) reaching 0.70 or higher. We then selected the top four lncRNAs, namely UCA1-201, HOTAIR, HYMA1 and MALAT1, to form a panel of urinary biomarkers. Using this panel, bladder cancer patients could be discriminated from urocystitis patients, with sensitivity and specificity reaching 95.7% and 94.3%, respectively. Finally, we confirmed the applicability of the four-lncRNA panel in an independent validation study that included 60 bladder cancer patients and 60 urocystitis patients. Our study paves the way for further studies aimed at large-scale clinical tests of developing lncRNA biomarkers in urine for bladder cancer diagnostics.

show abstract

Current insights into the oncogenic roles of lncRNA LINC00355

Shen,

Su,

Pan

et al. 2023

Cancer Innovation

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are a class of nonprotein‐coding transcripts that are longer than 200 nucleotides. LINC00355 is a lncRNA located on chromosome 13q21.31 and is consistently upregulated in various cancers. It regulates the expression of downstream genes at both transcriptional and posttranscriptional levels, including eight microRNAs (miR‐15a‐5p, miR‐34b‐5p, miR‐424‐5p, miR‐1225, miR‐217‐5p, miR‐6777‐3p, miR‐195, and miR‐466) and three protein‐coding genes (ITGA2, RAD18, and UBE3C). LINC00355 plays a role in regulating various biological processes such as cell cycle progression, proliferation, apoptosis, epithelial‐mesenchymal transition, invasion, and metastasis of cancer cells. It is involved in the regulation of the Wnt/β‐catenin signaling pathway and p53 signaling pathway. Upregulation of LINC00355 has been identified as a high‐risk factor in cancer patients and its increased expression is associated with poorer overall survival, recurrence‐free survival, and disease‐free survival. LINC00355 upregulation has been linked to several unfavorable clinical characteristics, including advanced tumor node metastasis and World Health Organization stages, reduced Karnofsky Performance Scale scores, increased tumor size, greater depth of invasion, and more extensive lymph node metastasis. LINC00355 induces chemotherapy resistance in cancer cells by regulating five downstream genes, namely HMGA2, ABCB1, ITGA2, WNT10B, and CCNE1 genes. In summary, LINC00355 is a potential oncogene with great potential as a diagnostic marker and therapeutic target for cancer.

show abstract

Urinary exosomal expression of long non-coding RNAs as diagnostic marker in bladder cancer

Cited by 73 publications

References 23 publications

Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma

Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma

A Panel of Urinary Long Non-coding RNAs Differentiate Bladder Cancer from Urocystitis

Current insights into the oncogenic roles of lncRNA LINC00355

Contact Info

Product

Resources

About